Abivax SA entered into an Underwriting Agreement on June 30, 2026, to issue and sell 6,400,000 American Depositary Shares at $125.00 per ADS. The company expects to receive approximately $759.8 million in net proceeds from the public offering. Abivax SA is a biotechnology company focused on developing therapies for inflammatory diseases.

Abivax SA announced positive topline results from Part 2 of its Phase 3 ABTECT 44-week maintenance trial for obefazimod in treating moderate to severely active ulcerative colitis. Patients treated with 50 mg obefazimod demonstrated clinical remission of 37.2% and clinical response of 61.5% at Week 44. The company plans to submit a New Drug Application (NDA) to the U.S. FDA in the fourth quarter of 2026. Abivax SA is a biotechnology company focused on developing oral miR-124 enhancers for inflammatory bowel disease.